CZClaus Zehetner

Claus Zehetner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claus Zehetner has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intraocular medulloepithelioma in an adult with unique AS-OCT imaging

    by Katharina Kirchmair, Claus Zehetner, Gertrud Haas, Alexander Franchi, Georg Blatsios

    Intraocular medulloepithelioma is primarily a pediatric, potentially malignant tumor. Only a few cases in adults have been described in the literature so far. We present a rare case of intraocular medulloepithelioma of the ciliary body in a 56-year-old male, characterized by multiple free-floating cysts in the anterior chamber, documented for the first time using anterior segment optical coherence tomography (AS-OCT). Histologically, the neoplasm consists of primitive neuroepithelial cells surrounded by hyaluronic acid-rich mesenchyme, forming characteristic cysts. Main differential diagnoses in adults include intraocular metastases and amelanotic melanoma. As cysts are rare in these neoplasms, AS-OCT may be a useful tool supporting diagnostic considerations. Despite the favorable survival prognosis in the absence of extraocular spread, the chance of bulbus-preserving therapy remains low. This report is important to raise awareness of intraocular medulloepithelioma in the differential diagnosis of ciliary body tumors in adults and to highlight the importance of AS-OCT in diagnosis.

  • Open Access

    Progerin mRNA Is Associated with Smoking and Signs of Increased Microvascular Damage in Patients with Diabetic Macular Edema

    by Marc-Michael Zaruba, Reinhard Angermann, Simon Staggl, Vivek Jeyakumar, Sofia Mair, Victoria Stöckl, Julia Neyer, Thomas Maurer, Maria Ungericht, Jasmina Gavranovic-Novakovic, et al.

    The premature aging disease Hutchinson–Gilford Syndrome (HGPS) is caused by defined mutations in the LMNA gene, resulting in the activation of a cryptic splice donor site, which leads to a defective truncated prelamin A protein called progerin. Notably, progerin expression has also been detected in non-mutated healthy individuals, and therefore, its involvement in the physiological aging process has been widely discussed. Since diabetes mellitus is associated with premature aging and increased cardiovascular mortality, we aimed to investigate the role of progerin expression in patients with diabetic retinopathy (DR). mRNA expression of progerin was analyzed in blood samples from 140 patients with DR who received anti-vascular endothelial growth factor (VEGF) therapy. Progerin mRNA levels were significantly lower in female compared to male patients (n = 42 vs. n = 98; 0.67 ± 0.19 vs. 0.89 ± 0.51, p = 0.006) and higher in patients with non-proliferative (NP)DR (n = 87 vs. n = 53; 0.9 ± 0.51 vs. 0.71 ± 0.29, p = 0.013) compared to those with proliferative (P)DR. Additionally, a positive correlation was found between progerin mRNA expression and the number of intravitreal anti-VEGF applications (n = 139, r = 0.21, p = 0.015), central macula thickness (CMT), (n = 137, r = 0.18, p = 0.036) and nicotine consumption (n = 105, r = 0.235, p = 0.002). The nuclear localization and significant upregulation of progerin mRNA and protein levels in dermal fibroblasts from HGPS donors emphasize its role in cellular aging mechanisms. Progerin mRNA levels were higher in patients with NPDR. CMT, number of intravitreal anti-VEGF therapy treatments, and cigarette consumption were positively related to progerin mRNA, suggesting an association with disease progression and premature aging.


  • Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD

    by Anna Lena Huber, Angelika Bauer, Julius Beirer, Katharina Frede, Katharina Kirchmair, Reinhard Angermann, Matus Rehak, Claus Zehetner, Yvonne Nowosielski

    Purpose Recently, a systemic counterregulatory response of angiopoietin-2 after intravitreal application of the anti vascular endothelial growth factor (anti-VEGF) drug aflibercept in neovascular age-related macular degeneration (nAMD) has been described. The aim of the study was to find out wether faricimab, a combined anti-VEGF/angiopoietin-2 drug, had an effect on systemic cytokine levels. Methods 20 women and 11 men (mean age 79.5 ± 7.3 years) were included into this cohort study. Plama levels of VEGF-A and angiopoietin-2 were determined before and after intravitreal application of faricimab (6 mg/0.05 ml/eye) using ELISA-technique. These results were correlated with central macular thickness (CMT). Responders were defined as having had CMT thinning ≥ 50 μm. Results CMT decreased from 384.8 ± 108.8 μm prior to intravitreal injection (IVI) to 286.1 ± 63 μm one month after IVI (p < 0.0001). Angiopoietin-2 levels increased from 526.9 ± 129 pg/ml to 597.2 ± 174.8 pg/ml (p = 0.0087) one week after IVI and dropped to 547.4 ± 165 pg/ml (ns) four weeks after IVI. Responders revealed higher angiopoietin-2 (p = 0.0035) as well as higher VEGF-A (p = 0.0248) levels throughout the study period compared to non-responders. Initial CMT revealed to be the only independent factor influencing CMT 4 weeks after IVI in linear regression models with a positive correlation between initial thickness and effect size. Conclusion The trending increase in systemic angiopoietin-2 levels, may be interpreted as an escape mechanism of the concomitant anti-VEGF component of therapy. Angiopoietin-2 levels could serve as a positive predictive factor of therapy response in the future. Further research regarding this effect as well as differences between responders and non-responders is mandatory. Key Messages What is known Bispecific antibodies may be more beneficial compared to monospecific antibodies in neovascular age related macular degeneration (nAMD). For monospecific antibodies, there are systemic effects on systemic vascular endothelial growth factor (VEGF) levels. What is new The knew bispecific antibody faricimab entails an increase in systemic angiopoietin-2 levels, as well as a decrease in VEGF levels. The increase in systemic angiopoietin-2 may be interpreted as a counterregulatory effect. The decrease in systemic VEGF levels resembles the effects of monospecific antibodies.


  • Open Access

    Optical Coherence Tomography Angiography Characteristics of Polypoidal Lesions in Caucasians

    by Daniel Ahmed-Balestra, Alexandra Graf, Martin Stattin, Anna-Maria Haas, Stefan Kickinger, Michael Jacob, Claus Zehetner, Katharina Krepler, Siamak Ansari-Shahrezaei

    Purpose. The aim of the study is to analyze the swept source‐optical coherence tomography angiography (SS‐OCTA) characteristics of polypoidal lesions in Caucasian patients. Methods. In this retrospective observational case series, 43 polypoidal lesions in 32 eyes of 32 patients were diagnosed using indocyanine green angiography (ICGA) and compared to SS‐OCTA at a tertiary medical retina center (Clinic Landstraße, Vienna Healthcare Group, Austria) between June 2017 and March 2020. Vascularity was identified by color‐coded B‐scan SS‐OCTA while morphology was described as revealed by en face SS‐OCTA after alignment with ICGA‐confirmed findings. Results. In total, SS‐OCTA detected all polypoidal lesions, as identified by ICGA. On B‐scan SS‐OCTA, circumscribed flow was detected in 33 (76.7%) polypoidal lesions and diffuse flow in 10 (23.3%) lesions. On en face SS‐OCTA, polypoidal lesions appeared morphologically as 19 tangled vessel balls (44.2%), 6 tangled vessel balls next to dilated vessels (13.9%), 8 vascular dilatations (18.6%), and 8 ill‐defined vascular networks (18.6%), leaving 2 lesions (4.6%) undetected. Circumscribed flow was significantly associated with tangled vessel balls (p = 0.005). Conclusion. This study highlights the importance of a multimodal imaging approach, including SS‐OCTA, for the evaluation of polypoidal lesions. Our findings suggest a morphological heterogeneity of vascular patterns in Caucasian patients with polypoidal lesions, as pictured by SS‐OCTA.


  • Open Access

    Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study

    by Reinhard Angermann, Alexander Franchi, Katharina Frede, Victoria Stöckl, Christoph Palme, Martina Kralinger, Claus Zehetner

    Background: This study aimed to analyse the persistence rates of treatment-naïve patients with neovascular age-related macular degeneration (nAMD) who received intravitreal aflibercept therapy in a universal health care system. Methods: In this single-centre retrospective cohort study, we audited data of 918 treatment-naïve patients who received exclusively intravitreal aflibercept therapy for nAMD between September 2015 and May 2021. The primary outcome measures were the rates of treatment nonpersistence (gap in ophthalmological care > 6 months) and long-term nonpersistence (> 12 months). Results: The rates of nonpersistence and long-term nonpersistence were 12.3% and 3.4% after one year; 22.4% and 9.5% after two years; and 38.3% and 19.3% after five years, respectively. Logistic regression analysis revealed that older age (p = 0.045), male sex (p = 0.039), requirement for caretakers or ambulance (p = 0.001), and low visual acuity of the study eye (p = 0.010) or fellow eye (p = 0.029) were independent risk factors for long-term nonpersistence. Patients aged > 80 and > 85 years (p = 0.013 and p = 0.022, respectively) had more than twice the risk for being nonpersistent to therapy within two years of follow-up compared with younger patients. Male patients (p = 0.033), patients requiring a caretaker (p = 0.038), and patients living > 60 km from the clinic (p = 0.029) had a 2 × higher risk of being persistently nonpersistent to therapy. Conclusions: Patients with nAMD who were treated with aflibercept had lower nonpersistence rates than those reported in current literature. Multiple independent risk factors were correlated with long-term nonpersistence, early nonpersistence, or complete loss to follow-up. Considering the possible consequences of reduced compliance, further strategies are urgently needed for patients at risk of nonpersistence to therapy.


  • Open Access

    Long-term persistence to aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: A retrospective study

    by Reinhard Angermann, Alexander Franchi, Katharina Frede, Victoria Stöckl, Christoph Palme, Martina Kralinger, Claus Zehetner

    Background This study aimed to analyse the persistence rates of treatment-naïve patients with neovascular age-related macular degeneration (nAMD) that received intravitreal aflibercept therapy in a universal health care system. Methods In this single-centre retrospective cohort study, we audited data of 918 treatment-naïve patients that received exclusively intravitreal aflibercept therapy for nAMD between September 2015 and May 2021. Primary outcome measures were nonpersistence (gap of ophthalmological care > 6 months) and long-term nonpersistence (> 12 months) rates. Results The rates of nonpersistence and long-term nonpersistence were 12.3% and 3.4%, respectively, after one year and 22.4% and 9.5%, respectively, after two years; and increased to 38.3% and 19.3%, respectively, after five years. Logistic regression analysis revealed that older age (p = 0.045), male patients (p = 0.039), patients requiring caretakers or ambulance (p = 0.001), and patients with a low visual acuity of the study eye (p = 0.010) or fellow eye (p = 0.029) were independent risk factors for long-term nonpersistence. Patients aged > 80 and > 85 years (p = 0.013 and p = 0.022, respectively) had more than twice the risk for being nonpersistent to therapy within two years of follow-up. Male patients (p = 0.033), patients requiring caretaker (p = 0.038), and patients living > 60 km from the clinic (p = 0.029) had a two times higher risk of being persistently nonpersistent to therapy. Conclusions We found a lower nonpersistence rate in patients with nAMD treated with aflibercept compared to that of current literature. Multiple independent risk factors were correlated with long-term nonpersistence, early nonpersistence, or complete loss to follow-up. Considering the possible consequences of reduced compliance, further strategies are urgently needed for patients at risk of nonpersistence to therapy.

  • Open Access

    Die Auswirkungen der COVID-19-Pandemie auf die Versorgungsqualität von therapienaiven PatientInnen mit neovaskulärer altersbedingter Makuladegeneration unter intravitrealer Aflibercept-Therapie

    by Reinhard Angermann, Alexander Franchi, Katharina Frede, Julia Rettenwander, Tanja Rettenwander, Julia Neyer, Martin Stattin, Martina Kralinger, Claus Zehetner

    Zusammenfassung: Fragestellung Ziel dieser Studie war es, die Versorgungsqualität von therapienaiven PatientInnen mit neovaskulärer altersbedingter Makuladegeneration (nAMD), die vor der Pandemie der Coronavirus-Krankheit 2019 (COVID-19) eine intravitreale Aflibercept-Therapie erhielten, mit PatientInnen zu vergleichen, die während der Pandemie dieselbe Therapie erhielten. Methode Es wurden von 297 therapienaiven PatientInnen u. a. die bestkorrigierte Sehschärfe (BCVA) als Logarithmus des minimalen Auflösungswinkels (logMAR) und die anatomischen Ergebnisse bei Diagnosestellung und bei jeder Nachuntersuchung erfasst. Therapienaive PatientInnen, bei denen mindestens 24 Monate vor dem 1. pandemiebedingten Lockdown eine Therapie begonnen und die somit ausschließlich vor der Pandemie (n = 123) behandelt wurden, wurden mit PatientInnen verglichen, die innerhalb von 12 Monaten vor dem 1. Lockdown die Therapie starteten und somit während der Pandemie (n = 174) behandelt wurden. Es wurden beide Gruppen über einen Zeitraum von 2 Jahren beobachtet. Resultate In der Gruppe, die vor der COVID-19-Pandemie behandelt wurde, blieb die Sehschärfe, verglichen zum Ausgangswert (0,58 ± 0,41 logMAR) bis zum Ende des Beobachtungszeitraums (0,54 ± 0,34 logMAR) stabil (p = 0,228). Der BCVA von PatientInnen, die während der COVID-19-Pandemie behandelt wurden, verschlechterte sich von 0,56 ± 0,35 bei Therapiestart zu 0,79 ± 0,43 logMAR (p = 0,010) zum Ende des Beobachtungszeitraums. Im Vergleich zu den PatientInnen, die vor der COVID-19-Pandemie behandelt wurden, zeigte die Gruppe, die während der Pandemie behandelt wurde, eine signifikant schlechtere Sehschärfe nach 6 Monaten (p = 0,041), 12 Monaten (p = 0,040), 18 Monaten (p = 0,024), 21 Monaten (p = 0,035) sowie nach 24 Monaten (p = 0,004). Darüber hinaus erhielt die während der COVID-19-Pandemie behandelte Gruppe im 2. Behandlungsjahr im Vergleich zur Gruppe, die vor der COVID-19-Pandemie behandelt wurde, weniger Aflibercept-Injektionen (3,94 ± 1,9 vs. 3,30 ± 1,6; p = 0,007) und weniger Nachsorgeuntersuchungen (2,71 ± 1,2 vs. 2,16 ± 0,9; p < 0,001). Schlussfolgerung PatientInnen mit nAMD, die während der COVID-19-Pandemie behandelt wurden, hatten eine signifikant schlechtere Visusentwicklung über einen Beobachtungszeitraum von 2 Jahren als PatientInnen, die vor der Pandemie behandelt wurden. Der erschwerte Zugang zur Versorgung könnte auf die Einschränkungen zurückzuführen sein, die aufgrund der COVID-19-Pandemie auferlegt wurden.


  • Two Cases of Acute Macular Neuroretinopathy Associated with the Adenovirus-based COVID-19 Vaccine Vaxzevria (Astrazeneca)

    by Alexander Franchi, Teresa Rauchegger, Christoph Palme, Katharina Frede, Gertrud Haas, Georgios Blatsios, Martina Kralinger, Claus Zehetner

    To report two cases of acute macular neuroretinopathy (AMN) in young female patients following the administration of the adenovirus-based coronavirus disease 2019 (COVID-19) vaccine Vaxzevria (AstraZeneca). Spectral-domain optical coherence tomography and infrared imaging were used to confirm the diagnosis of AMN. Both patients showed a parafoveal hyperreflective band in the outer nuclear layer, disruption of the ellipsoid and interdigitation zones of the photoreceptor layers, and correlating hyporeflective areas on the near-infrared images. Both patients presented with flu-like fever and sudden onset of fortifications within 48 hours of vaccination. One patient showed altered flow in the deep capillary plexus and highly elevated thrombotic parameters. We report a possible association between immune-mediated AMN and the administration of adenovirus-based COVID-19 vaccine Vaxzevria.


  • Open Access

    Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A Five-Year Follow-Up Investigation

    by Reinhard Angermann, Alexander Franchi, Victoria Stöckl, Julia Rettenwander, Tanja Rettenwander, David Goldin, Martin Stattin, Martina T. Kralinger, Claus Zehetner

    Introduction We aimed to evaluate visual and anatomical outcomes among eyes with neovascular age-related macular degeneration (nAMD) that were persistent to intravitreal aflibercept therapy compared to those that were nonpersistent to therapy. Methods We audited 648 treatment-naïve eyes of 559 patients regarding visual acuity (VA) given as the logarithm of the minimum angle of resolution (logMAR) and anatomic outcomes at baseline and at each subsequent follow-up visit for up to 5 years. Nonpersistence was defined as a visit-free interval of > 6 months. Results Among the enrolled eyes, 405 were persistent to the therapy and 243 (37%) were nonpersistent, of which 161 (66%) eyes returned for further therapy after a gap of clinical care. In the nonpersistent group, we observed a decline from 0.58 ± 0.35 to 0.92 ± 0.57 logMAR (p = 0.01) after 60 months. Compared with the persistent group, the nonpersistent group had worse visual outcomes at their 33-month (p = 0.03), 42-month (p = 0.01), 51-month (p = 0.001) and 60-month (p = 0.01) visits. Additionally, 5/405 (1.2%) eyes in the persistent group and 8/161 (5.0%) eyes in the nonpersistent group developed an end-stage disease with a subfoveal fibrosis during the observational period (p = 0.013). Conclusion We found that eyes with nAMD that were nonpersistent to intravitreal aflibercept therapy experienced statistically significantly worse VA compared to eyes persistent to therapy within 3 years. Moreover, eyes in the nonpersistent group had a four-fold higher risk of developing a fovea-involving fibrosis. Considering the potential irreversible deterioration with respect to best-corrected VA within nAMD, strategies need to be developed for patients at risk of nonpersistence to therapy.


  • Open Access

    Efficiency benchmarks in the surgical management of primary rhegmatogenous retinal detachment: a monocentric register cohort study of operating room time metrics and influential factors

    by Reinhard Angermann, Anna Lena Huber, Markus Hofer, Yvonne Nowosielski, Stefan Egger, Martina T Kralinger, Claus Zehetner

    Objectives To investigate the effect of clinical, methodological and logistic factors on operating room (OR) efficiency in the surgical management of primary rhegmatogenous retinal detachment (RRD). Design Monocentric retrospective register cohort study. Setting Single tertiary centre in the western region of Austria. Participants We audited patients diagnosed with primary RRD who were treated between January 2014 and August 2019. In total, 783 eyes of 776 consecutive patients were included in this study. Various risk factors affecting OR time efficiency and anatomical success after pars plana vitrectomy (PPV) procedures and scleral buckle (SB) surgery were analysed. Primary and secondary outcome measures OR efficiency was the primary outcome measure. Secondary outcome measures were the primary success rate after PPV procedures and SB surgery. Results PPV was performed in 641 (81.9%) eyes and SB surgery in 142 (18.1%) eyes. Mean surgical times in PPV and SB under retrobulbar anaesthesia (RA) were 74.0 (±32.6) min and 62.1 (±24.6) min (pConclusions OR coordinators should consider various independent clinical (giant tear, PVR-C, advanced detachment), methodological (PPV vs SB) and logistic (GA vs RA, after-hours setting and surgeon experience) factors to improve the success rate and surgical management planning of RRD accurately while optimising OR resources and staff efficiency.